An open-label study to evaluate the safety and long-term clinical efficacy of imiquimod 5% cream applied once daily 5 days per week for 6 weeks in the treatment of superficial basal cell carcinoma
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2008
At a glance
- Drugs Imiquimod (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 05 Feb 2008 Status changed from in progress to completed.
- 10 Nov 2005 New trial record.